Fennec Pharmaceuticals is a small stage biotechnology company focused on the development of PEDMARK TM (a unique formulation of Sodium Thiosulfate) for the prevention of ototoxicity from cisplatin in pediatric patients.
PEDMARK is an investigational drug and has not yet been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority.
Publications & Presentations
Helping the Kids of Today Become the Adults of Tomorrow
Hearing loss is a devastating and life-long impact on quality of life for children that can cause grade setbacks and learning problems. Fennec advocates for a better quality of life.
Fennec News
- November 12th, 2019 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS
- October 2nd, 2019 FENNEC TO PRESENT AT THE 2019 CANTOR GLOBAL HEALTHCARE CONFERENCE ON OCTOBER 4, 2019
- September 24th, 2019 FENNEC APPOINTS JODI A. COOK, PhD TO ITS BOARD OF DIRECTORS